GSK to Acquire Trispecific T Cell Engager for Multiple Myeloma From Chimagen in Deal Worth Up to $750 Million

The programme is expected to enter phase I trials in 2027, with GSK describing the targeted approach as aiming for deeper, more durable responses than existing T cell engagers.

Key Points

  • GSK will acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, with phase I trials planned for 2027.
  • The asset binds T cells and two validated tumour-associated antigens; GSK says the design aims for deeper, more durable responses and improved tolerability over existing T cell engagers.
  • The deal carries a total potential value of up to $750 million, including an upfront payment and success-based milestones.

GSK plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire a trispecific T cell engager (TCE) for multiple myeloma. GSK plans to develop and commercialise the asset, with the programme expected to enter phase I trials in 2027.

TCEs have shown transformational efficacy in multiple myeloma but have been associated with difficult tolerability profiles. The Chimagen trispecific asset is designed to address this by binding to T cells while simultaneously targeting two strategically selected and validated tumour-associated antigens. GSK describes this targeted approach as aiming to achieve a deeper and more durable response compared with existing TCEs, along with an improved tolerability profile, which could enable broader adoption and earlier use in multiple myeloma treatment. The US TCE market for multiple myeloma is expected to exceed $10 billion by 2032.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said, “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease.”

Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences, said, “Our mission has always been to translate cutting-edge innovation into life-changing medicines. Working with GSK combines our precision T-cell engager programme with their global development and commercial capabilities to redefine care for multiple myeloma patients. This agreement also marks another major milestone for our platforms as we continue to build an industry-leading pipeline of multi-specific antibody candidates.”

Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year. While generally considered treatable, it is not currently curable, and research into new therapies is vital as the disease commonly becomes refractory to available treatments.

The agreement builds on GSK’s existing relationship with Chimagen. The companies previously agreed that GSK would acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted TCE currently in phase I trials for B-cell malignancies and B-cell dependent autoimmune disorders.

Financial terms

Under the agreement, GSK will pay an upfront fee to acquire full global rights to the TCE programme. Chimagen will also be eligible to receive success-based development and commercial milestone payments. The agreement has a total potential value of up to $750 million and is subject to customary closing conditions.

Chimagen Biosciences

Chimagen Biosciences is a clinical-stage biotechnology company focused on discovering and developing multi-specific T cell engagers and NK cell engagers generated by proprietary antibody engineering platforms. Its focus is on therapies for cancer and autoimmune diseases.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.